Author

M. Z. Chaudhry

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Bioengineering· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:cell type annotation· 2 Organism:human· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

L. Cicin-Sain· 4 shared K. Eschke· 3 shared Y. Kim· 3 shared F. Bertoglio· 2 shared M. Hoffmann· 2 shared M. Hust· 2 shared M. Ruschig· 2 shared A. Frenzel· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

L. Cicin-Sain

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

NFAT signaling is indispensable for persistent memory responses of MCMV-specific CD8+ T cells

M. Z. Chaudhry, L. Borkner, F. Berberich-Siebelt, L. Cicin-Sain

This study shows that NFATc1 and NFATc2 are essential for the long-term inflation of MCMV-specific CD8 T cells during viral latency, but not for acute infection responses.

bioRxiv · May 2, 2023 · PreprintImmunology

A single-dose MCMV-based vaccine elicits long-lasting immune protection in mice against distinct SARS-CoV-2 variants

K. Metzdorf, H. Jacobsen, Y. Kim, L. G. Teixeira Alves, U. Kulkarni, K. Eschke, M. Z. Chaudhry, M. Hoffmann, F. Bertoglio, M. Ruschig, M. Hust, M. C. Brdovcak, J. Materljan, M. Sustic, A. Krmpotic, , L. Cicin-Sain

A single dose of a recombinant murine CMV vaccine expressing SARS-CoV-2 spike protein provides long-lasting immunity against multiple variants in mice.

bioRxiv · Nov 25, 2022Immunology

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

F. Bertoglio, V. Fühner, M. Ruschig, P. A. Heine, L. Abasi, T. Klünemann, U. Rand, D. Meier, N. Langreder, S. Steinke, R. Ballmann, K.-T. Schneider, K. D. R. Roth, P. Kuhn, P. Riese, , M. Hust

The paper describes the selection of a SARS-CoV-2 neutralizing antibody from COVID-19 patients using phage display, showing it binds the ACE2-RBD interface and remains effective against emerging RBD mutations.

Cell Reports · Jul 1, 2021Peer-reviewedBioengineering

Rapid SARS-CoV-2 Adaptation to Available Cellular Proteases

M. Z. Chaudhry, K. Eschke, M. Hoffmann, M. Grashoff, L. Abassi, Y. Kim, L. Brunotte, S. Ludwig, A. Kroeger, F. Klawonn, S. Pöhlmann, L. Cicin-Sain

This study shows SARS-CoV-2 adapts to Vero E6 cells by losing the furin cleavage motif in spike protein, but retains wildtype sequences, enabling reverse adaptation when passaged on human lung cells.

bioRxiv · Aug 10, 2020Microbiology